Loading…
Organogenesis Holdings Inc. is projected to rise to $2.57 by 2027, a +7% move from its current price of $2.40. ORGO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.34 | $2.40 | $2.46 | +0.03% |
| Jul 14 | $2.32 | $2.40 | $2.48 | +0.07% |
| Jul 15 | $2.31 | $2.40 | $2.50 | +0.10% |
| Jul 16 | $2.29 | $2.40 | $2.52 | +0.13% |
| Jul 17 | $2.28 | $2.40 | $2.53 | +0.17% |
| Jul 18 | $2.27 | $2.40 | $2.55 | +0.20% |
| Jul 19 | $2.26 | $2.41 | $2.56 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.26 | $2.41 | $2.56 | +0.24% |
| Week 2 | $2.21 | $2.41 | $2.63 | +0.47% |
| Week 3 | $2.17 | $2.42 | $2.69 | +0.71% |
| Week 4 | $2.14 | $2.42 | $2.75 | +0.94% |
| Week 5 | $2.11 | $2.43 | $2.79 | +1.18% |
| Week 6 | $2.09 | $2.43 | $2.84 | +1.42% |
| Week 7 | $2.07 | $2.44 | $2.88 | +1.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Organogenesis Holdings Inc. is a healthcare company focused on regenerative medicine. It develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
Its portfolio includes Affinity and Novachor, amnion and chorion placental allografts for chronic and acute wounds, and Apligraf, a bi-layered skin substitute for venous leg ulcers and diabetic foot ulcers. It also markets Dermagraft, NuShield, PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for open wounds in surgical settings, as well as placental tissue grafts that can be stored at room temperature. In addition, TransCyte, FortiShield, and PuraForce are among its offerings, and ReNu is in Phase 3 for knee osteoarthritis.
The company is headquartered in Canton, Massachusetts.
Organogenesis Holdings Inc. (ORGO) is a healthcare stock with a current price of $2.36 and a market capitalization of $303.67M. It is ranked 3524 by market cap among listed assets.
The forecast indicates a path of gradual price movement with a transition to bullish sentiment in later years. The 2026 average price is $2.36, and the multi-year outlook shows higher averages later, with 2030 at an average of $2.66 and 2050 at an average of $8.77, accompanied by progressively larger ROIs (e.g., 12.8% in 2030, 271.6% by 2050).
A major floor 15.0% below — a decisive break under it would weaken the trend.
The nearest floor, 6.7% below — buyers have tended to step in here.
The nearest ceiling, 9.2% above — a clean break opens room to run.
A major ceiling 20.8% above — clearing it would confirm fresh momentum.
Key ORGO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ORGO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.46 | Sell | $2.44 | Sell |
| MA 10 | $2.44 | Sell | $2.44 | Sell |
| MA 20 | $2.42 | Sell | $2.44 | Sell |
| MA 50 | $2.46 | Sell | $2.49 | Sell |
| MA 100 | $2.60 | Sell | $2.76 | Sell |
| MA 200 | $3.58 | Sell | $3.21 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.50 | Neutral |
| Stoch RSI (14) | 25.20 | Neutral |
| CCI (20) | -44.51 | Neutral |
| Williams %R (14) | -71.43 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -1.23 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 28.57 | Neutral |
| TRIX (15) | -0.05 | Sell |
| Awesome (5,34) | 0.01 | Buy |
| Ultimate (7,14,28) | 45.11 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 2.47 | Sell |
| ADX (14) | 6.26 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is neutral. RSI14 is 40, and the price remains below the SMA200 while hovering near the SMA50 at $2.45 and the $3.64 mark respectively.
Support is seen at $2.24 and resistance at $2.66, with the 30-day price range ranging from $2.01 to $2.78.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.24 | $2.40 | $3.07 | 0% | Neutral | |
| $2.07 | $2.57 | $3.36 | +7% | Neutral | |
| $1.94 | $2.46 | $3.32 | +3% | Neutral | |
| $2.14 | $2.77 | $3.83 | +15% | Neutral | |
| $2.33 | $3.07 | $4.34 | +28% | Bullish | |
| $2.55 | $3.42 | $4.93 | +42% | Bullish | |
| $2.86 | $3.88 | $5.69 | +62% | Bullish | |
| $2.89 | $3.99 | $5.94 | +66% | Bullish | |
| $2.92 | $4.08 | $6.16 | +70% | Bullish | |
| $2.97 | $4.19 | $6.42 | +75% | Bullish | |
| $4.08 | $6.10 | $9.88 | +154% | Bullish | |
| $7.08 | $11.63 | $20.43 | +385% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.24 | $2.40 | $2.82 | +0.00% |
| August 2026 | $2.04 | $2.39 | $2.89 | -0.22% |
| September 2026 | $2.09 | $2.47 | $3.01 | +3.34% |
| October 2026 | $2.09 | $2.48 | $3.04 | +0.26% |
| November 2026 | $2.04 | $2.44 | $3.02 | -1.54% |
| December 2026 | $2.06 | $2.47 | $3.07 | +1.17% |
Click any year to see its month-by-month ORGO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Organogenesis Holdings Inc.'s 2026 outlook centres on $2.40, within a $2.24 to $3.07 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ORGO could reach as high as $3.36, with a base case around $2.57 and support toward $2.07 — roughly +7% from $2.40. A consolidation phase looks the most probable path here.
Expect ORGO to range from $1.94 to $3.32 through 2028. The $2.46 average target implies a +3% move from current prices. That is -4% versus the projected 2027 average. Price action looks broadly range-bound.
The ORGO price prediction for 2029 points to an average of $2.77 (low $2.14, high $3.83) — a potential gain of +15% on today's $2.40. A consolidation phase looks the most probable path here.
In 2030, ORGO is projected to trade between $2.33 and $4.34, averaging $3.07 — a potential gain of +28% from today's $2.40. That is up +11% on the projected 2029 average. Momentum favours further upside here.
Organogenesis Holdings Inc.'s 2031 outlook centres on $3.42, within a $2.55 to $4.93 range. That is up +11% on the projected 2030 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ORGO could reach as high as $5.69, with a base case around $3.88 and support toward $2.86 — roughly +62% from $2.40. Momentum favours further upside here.
Expect ORGO to range from $2.89 to $5.94 through 2033. The $3.99 average target implies a +66% move from current prices. That is up +3% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ORGO price prediction for 2034 points to an average of $4.08 (low $2.92, high $6.16) — a potential gain of +70% on today's $2.40. Momentum favours further upside here.
In 2035, ORGO is projected to trade between $2.97 and $6.42, averaging $4.19 — a potential gain of +75% from today's $2.40. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Organogenesis Holdings Inc.'s 2040 outlook centres on $6.10, within a $4.08 to $9.88 range. That is up +45% on the projected 2035 average. That marks a +154% change versus current levels. Momentum favours further upside here.
By 2050, ORGO could reach as high as $20.43, with a base case around $11.63 and support toward $7.08 — roughly +385% from $2.40. Buyers look set to stay in control over this stretch.
Investing $1,000 in ORGO today (≈ 416.666667 ORGO) could be worth
$4,846.43
+$3,846.43 (+385%) by 2050 · US Dollar
Based on the average projected ORGO price of $11.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ORGOwould be worth at today's price.
$1,000 invested in ORGO on Jul 10, 2025 (≈ 227.272722 ORGO) would be worth
$545.45
-$454.55 (-45.5%) today · 0.55× · US Dollar
Based on a ORGO entry price of $4.4 vs. today's $2.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.36 | $1,016.95 | +1.7% |
| 1 month ago | $2.47 | $971.66 | -2.8% |
| 3 months ago | $2.38 | $1,008.4 | +0.8% |
| 6 months ago | $4.23 | $567.38 | -43.3% |
| 1 year ago | $4.4 | $545.45 | -45.5% |
| All time (5.0y) ago | $16.25 | $147.69 | -85.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ORGO forecast.
Our base-case forecast reaches $4.80 around 2040.
Implied market cap at $4.80: $617.64M
Looking across the multi-year forecast, the 2030 average price is $2.66 with a 2030 ROI of 12.8 and neutral sentiment. The trend shifts to bullish from 2031 onward, with the 2031 average $2.91 and 2035 average $3.50 as part of a rising trajectory to $8.77 by 2050 and a 271.6 ROI in that year. The forecast also shows substantial upside in the 2040 period, where the average price is $4.88 and ROI reaches 106.9, under a bullish outlook through 2040 and 2050.
Across these years, volatility is noted at about 50% annually, which implies meaningful price swings and upside as sentiment shifts to bullish. Overall, the outlook points to a gradual climb from current levels toward higher targets, with the most pronounced gains occurring after 2030.
Tap a question to reveal the answer.
2030: average price $2.66; range $2.01 to $3.80; ROI 12.8; sentiment NEUTRAL.
Forecasts show positive ROIs in several years, with 2031 ROI 23.5 and 2050 ROI 271.6, and a shift to bullish sentiment from 2031 onward, though prices are still subject to uncertainty.
The 2050 maximum forecast is $15.63, with a 2050 average of $8.77, indicating the potential to exceed $10 in the higher-end scenario by 2050.
RSI 14 is 40 (neutral). The price sits around SMA50 at $2.45 and below SMA200 at $3.64, with support at $2.24 and resistance at $2.66; 30-day range is $2.01–$2.78.
Current price is $2.36 and market capitalization is $303.67M; the asset is ranked 3524.
Organogenesis Holdings Inc. Community Discussion
0Share your Organogenesis Holdings Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.